Are you Dr. Lopatin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1233 Howard St
Apt 716
San Francisco, CA 94103Phone+1 415-935-1874
Summary
- Dr. Uri Lopatin, MD is an infectious disease specialist in San Francisco, California. He is currently licensed to practice medicine in New York.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2003 - 2005
- NYU Grossman School of MedicineResidency, Internal Medicine, 2001 - 2003
- University of WashingtonInternship, Internal Medicine, 2000 - 2001
- Rutgers New Jersey Medical SchoolClass of 2000
Certifications & Licensure
- NY State Medical License 2002 - 2025
Publications & Presentations
PubMed
- 5 citationsEvaluation ofantiviral activity of SARS-CoV-2 Minhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions.Xiao Tong, Walter Keung, Lee D Arnold, Laura J Stevens, Andrea J Pruijssers
Antimicrobial Agents and Chemotherapy. 2023-11-15 - 70 citationsSafety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.Man-Fung Yuen, Kosh Agarwal, Edward Gane, Christian Schwabe, Sang Hoon Ahn
The Lancet. Gastroenterology & Hepatology. 2020-02-01 - 21 citationsSafety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.Mark S Sulkowski, Kosh Agarwal, Xiaoli Ma, Tuan T Nguyen, Eugene R Schiff
Journal of Hepatology. 2022-11-01
Press Mentions
- Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 InfectionsAugust 26th, 2021
- Pardes Biosciences Appoints Deborah M. Autor, J.D. (’92) and Laura J. Hamill to Board of DirectorsAugust 5th, 2021
- Shasqi Completes $10 Million Series A FinancingOctober 31st, 2019
- Join now to see all
Professional Memberships
- Member